Apremilast retention rate in clinical practice : observations from an Italian multi-center study
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR)..
OBJECTIVE: There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence.
METHODS: In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan-Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant.
RESULTS: The 356 enrolled patients (median age 60 [interquartile range IQR 52-67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7-34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96-0.99; p = 0.048 and 0.54 IQR 0.31-0.95; p = 0.03).
CONCLUSION: Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points • Apremilast retention rates in this real-life cohort and trials are comparable. • The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years). • No different or more prevalent adverse events were observed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 41(2022), 10 vom: 07. Okt., Seite 3219-3225 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
4Z8R6ORS6L |
|---|
| Anmerkungen: |
Date Completed 22.09.2022 Date Revised 22.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-022-06255-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343174375 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343174375 | ||
| 003 | DE-627 | ||
| 005 | 20231226015819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-022-06255-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343174375 | ||
| 035 | |a (NLM)35796847 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ariani, Alarico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apremilast retention rate in clinical practice |b observations from an Italian multi-center study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2022 | ||
| 500 | |a Date Revised 22.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR). | ||
| 520 | |a OBJECTIVE: There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence | ||
| 520 | |a METHODS: In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan-Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant | ||
| 520 | |a RESULTS: The 356 enrolled patients (median age 60 [interquartile range IQR 52-67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7-34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96-0.99; p = 0.048 and 0.54 IQR 0.31-0.95; p = 0.03) | ||
| 520 | |a CONCLUSION: Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points • Apremilast retention rates in this real-life cohort and trials are comparable. • The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years). • No different or more prevalent adverse events were observed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Apremilast | |
| 650 | 4 | |a Drug retention rate | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a apremilast |2 NLM | |
| 650 | 7 | |a UP7QBP99PN |2 NLM | |
| 700 | 1 | |a Parisi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Del Medico, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Visalli, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Aldo Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Lumetti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Caccavale, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Scolieri, Palma |e verfasserin |4 aut | |
| 700 | 1 | |a Andracco, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Girelli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bravi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Colina, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ianniello, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Franchina, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Platè, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Di Donato, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Amato, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santilli, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetta, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigoni, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Mozzani, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Sandri, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzese, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Paroli, Marino |e verfasserin |4 aut | |
| 700 | 1 | |a Fusaro, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Becciolini, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 41(2022), 10 vom: 07. Okt., Seite 3219-3225 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:10 |g day:07 |g month:10 |g pages:3219-3225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-022-06255-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 10 |b 07 |c 10 |h 3219-3225 | ||